BioNTech SE - ADR Stock

$111.00

1.67% today

Nasdaq, Jul 14, 10:03 pm CET

ISIN

US09075V1026

Symbol

BNTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BioNTech SE - ADR Stock price

$111.00

+28.23 34.10% 5Y

Nasdaq, Closing price Mon, Jul 14 2025

-1.89 1.67%

ISIN

US09075V1026

Symbol

BNTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$27.4b

Enterprise Value

$8.1b

Net debt

positive

Cash

$19.6b

Shares outstanding

240.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.5 | 11.1

EV/Sales

2.5 | 3.3

EV/FCF

negative

P/B

1.2

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$3.2b | $2.5b

EBITDA

$-1.0b | $-1.8b

EBIT

$-1.4b | $-2.2b

Net Income

$-777.7m | $-1.5b

Free Cash Flow

$-285.9m

Growth (TTM | estimate)

Revenue

-28.0% | -23.6%

EBITDA

-181.5% | -82.6%

EBIT

-232.8% | -59.0%

Net Income

-171.5% | -91.1%

Free Cash Flow

-105.2%

Financial Health

Equity Ratio

86.2%

Return on Equity

-3.4%

ROCE

-5.8%

ROIC

-34.9%

Debt/Equity

0.0

EPS

$-3.3

FCF per Share

$-1.2

Short interest

6.6%

Employees

Rev per Employee

$470.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

??

27 Analysts have issued a BioNTech SE - ADR forecast:

20x Buy

74%

7x Hold

26%

More details on Analyst Estimates Including Price Targets

27 Analysts have issued a BioNTech SE - ADR forecast:

Buy

74%

Hold

26%

Analyst Estimates with Stock Price Targets

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	3,216 3,216	28% 28% 100%
- Direct Costs	486 486	31% 31% 15%
Gross Profit	2,730 2,730	27% 27% 85%
- Selling and Administrative Expenses	700 700	7% 7% 22%
- Research and Development Expense	2,635 2,635	30% 30% 82%
EBITDA	-1,006 -1,006	182% 182% -31%
- Depreciation and Amortization	348 348	62% 62% 11%
EBIT (Operating Income) EBIT	-1,355 -1,355	233% 233% -42%
Net Profit	-778 -778	172% 172% -24%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BioNTech SE - ADR Stock News

Negative

Reuters

●

4 days ago

Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-running legal dispute between the two sides.

marktEINBLICKE

●

18 days ago

Krebsoffensive: BioNTech stärkt sich mit CureVac-Übernahme

Die Aktie schwankt, doch die Strategie ist klar: BioNTech setzt auf mRNA-Innovationen – und CureVac soll das Tempo weiter erhöhen.

Positive

Schaeffers Research

●

about one month ago

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office	Germany
CEO	Ugur Sahin
Employees	6,772
Founded	2008
Website	www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now